MiniMed Files Form S-4 for Medtronic Exchange Offer

NORTHRIDGE, Calif., Sept. 14, 2026 /CourierPR/ -- MiniMed, a global leader in insulin delivery, has filed a Form S-4 Registration Statement with the Securities and Exchange Commission (SEC) in connection with an exchange offer announced by Medtronic plc. According to the press release, Medtronic is offering to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares, for outstanding Medtronic ordinary shares that are validly tendered and not withdrawn. If the exchange offer is oversubscribed, Medtronic intends to exchange all of its remaining interest in MiniMed, which is an additional 27,452,053 shares, without extending the offer period.

Que Dallara, CEO of MiniMed, stated, "With the exchange offer underway, our separation from Medtronic is entering the final stage. It does not change who we serve, but it gives us complete autonomy over our capital allocation, product roadmap, and speed. Independence does not make the job easier; it simply means our execution is entirely in our own hands."

The exchange offer is subject to the terms of the offer and is neither an offer to sell nor a recommendation as to whether investors should participate. The offer is made solely by the prospectus referenced in the press release. MiniMed currently owns approximately 89.86% of the total outstanding shares of MiniMed common stock. If the exchange offer, including all related transactions, is effectuated, Medtronic will no longer hold an equity stake in MiniMed.

This press release is for informational purposes only and does not constitute an offer to sell or exchange any securities. Investors and security holders are urged to read the Prospectus, which contains important information about the exchange offer, Medtronic, MiniMed, and related matters. The Prospectus can be obtained free of charge from the SEC's website at www.sec.gov or by clicking on the appropriate link at www.dfking.com/MDTSeparation.